Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

por Young, Mary H., Pietz, Greg, Whalen, Elizabeth, Copeland, Wilbert, Thompson, Ethan, Fox, Brian A., Newhall, Kathryn J.
Publicado 2021

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

por Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Hellmann, Andrzej, Taussig, David C., Tormo, Mar, Voso, Maria Teresa, Cavenagh, James, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Silverman, Lewis R.
Publicado 2022

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

por Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Ogasawara, Ken, Cavenagh, James, Silverman, Lewis R., Voso, Maria Teresa, Hellmann, Andrzej, Tormo, Mar, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Garcia-Manero, Guillermo
Publicado 2022

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

por Danziger, Samuel A., McConnell, Mark, Gockley, Jake, Young, Mary H., Rosenthal, Adam, Schmitz, Frank, Reiss, David J., Farmer, Phil, Alapat, Daisy V., Singh, Amrit, Ashby, Cody, Bauer, Michael, Ren, Yan, Smith, Kelsie, Couto, Suzana S., van Rhee, Frits, Davies, Faith, Zangari, Maurizio, Petty, Nathan, Orlowski, Robert Z., Dhodapkar, Madhav V., Copeland, Wilbert B., Fox, Brian, Hoering, Antje, Fitch, Alison, Newhall, Katie, Barlogie, Bart, Trotter, Matthew W. B., Hershberg, Robert M., Walker, Brian A., Dervan, Andrew P., Ratushny, Alexander V., Morgan, Gareth J.
Publicado 2020